Titan Eyeplus

Sector: Retail — Eyewear & Optical  |  HQ: Bengaluru, Karnataka  |  Founded: Unknown  |  Employees: ~21,000 (Titan Company Ltd. parent, optical division portion unknown)

Listed as: Privately held  |   |  Website →

Company overview

Titan Eyeplus is the eyewear retail arm of Titan Company Ltd., a listed Tata Group conglomerate. It operates a pan-India network of optical retail stores offering prescription spectacles, sunglasses, contact lenses, and eye care services. The brand leverages Titan Company's established retail expertise and brand trust to compete in India's growing optical retail market, which includes both branded chains and independent opticians.

Recent developments

2020-2024

Titan Eyeplus has pursued significant manufacturing scale-up and product innovation over the period under review. The company launched India's first anti-viral frame in late 2020 [3] and introduced anti-fog lenses to address pandemic-era consumer needs [5]. On the production side, Titan Eyeplus established a satellite lens manufacturing facility in Madhyamgram, Kolkata in December 2024 [6], building on earlier plans to launch lens manufacturing units in 2016 [4]. The omnichannel strategy was reinvented in 2018 [7], positioning the brand for multi-channel retail integration ahead of comparable players. The launch of the premium Zefr glasses brand in August 2023 [2] signals a move upmarket, while Lenskart's reported sales surpassing Titan Eyeplus despite its own Rs 380 crore plant investment highlights intensifying competitive dynamics in India's optical retail sector [1].

Beyond commercial operations, Titan Eyeplus has engaged in large-scale public health initiatives, notably launching eye screening programs for 10 million Indians in October 2021 [8]. The company has also expanded its product portfolio with customizable frame offerings such as Flip, launched in 2016 [9], demonstrating a focus on personalization as a differentiator in the competitive eye care market.

Sources (9)

1. Lenskart to invest Rs 380cr in 2nd plant, sales go past Titan Eyeplus - The Times of India · The Times of India · Wed, 26 Aug 2020
2. Titan Eyeplus launches premium glasses brand Zefr - FashionNetwork India · FashionNetwork India · Mon, 28 Aug 2023
3. India’ first Anti-Viral Frame launched by Titan Eyeplus - afaqs! · afaqs! · Wed, 04 Nov 2020
4. Titan Eyeplus to launch two lens manufacturing units - Business Standard · Business Standard · Wed, 11 May 2016
5. Titan Eyeplus Ensures Comfort and Clear Vision with the New Anti-Fog Lenses - BW Businessworld · BW Businessworld · Mon, 24 Aug 2020
6. Kolkata: Titan Eyeplus launches satellite lens manufacturing facility in Madhyamgram - Indiablooms · Indiablooms · Tue, 17 Dec 2024
7. Titan Eyeplus reinvents Omnichannel - MultiVu · MultiVu · Tue, 09 Oct 2018
8. On World Sight Day, Titan Eyeplus Initiates Eye Screening for 10 Million Indians to enable a lifetime of clear sight for all - Adgully.com · Adgully.com · Thu, 14 Oct 2021
9. Titan Eyeplus announces launch of customizable spectacle frames Flip - India Retailing · India Retailing · Wed, 03 Aug 2016

Financial performance and recent trajectory

Disclosed revenue (FY25): Not separately disclosed in segment-wise FY 2024-25 reporting.

Competitive position

Titan Eyeplus competes with large organised optical retailers such as Lenskart (backed by Premji Invest and SoftBank), Vision Express (part of the GrandVision/Shenzhen Holdings group), and Owndays, as well as numerous independent optical stores. Titan Eyeplus benefits from Titan's brand equity, retail footprint, and supply chain, though Lenskart holds a dominant position in India's online and omnichannel eyewear market.

Key risks

Intense competition from Lenskart, which dominates India's online and omnichannel eyewear segment with aggressive pricing and rapid expansion Dependence on Titan Company Ltd. for capital allocation and strategic prioritisation; the eyewear business is a smaller segment compared to watches and jewellery Operational challenges including real estate costs, trained optician availability, and inventory management across a large store network Shifts in consumer purchasing behaviour toward online eyewear platforms, which may erode footfall at physical stores if the omnichannel strategy lags

Outlook

Titan Eyeplus is a participant in the Indian eye care / optical store business plan & category, which forms part of the broader Healthcare space. The Indian eye care / optical store business plan & market continues to evolve with rising organised share, premiumisation, distribution expansion, and a regulatory architecture covering the Companies Act 2013, the Income Tax Act 1961, the CGST Act 2017, the Legal Metrology Act 2009, and sectoral statutes including the Food Safety and Standards Act 2006 (for food and beverage subsegments), the Drugs and Cosmetics Act 1940 (for pharmaceutical or healthcare adjacencies), the Environment Protection Act 1986 (for emissions and effluents), and labour codes consolidated under the four 2020 labour codes. In KAMRIT's project report framework for this category, the competitive set typically includes pan-India branded leaders, multinational subsidiaries, mid-sized regional players, and a long tail of MSME participants. The structural attractiveness of the category for new entrants is a function of (a) market growth rate, (b) the share that remains with unorganised or fragmented operators, (c) the cost of regulatory compliance, and (d) the capex intensity of plant and machinery. The KAMRIT bankable DPR for this category structures a new entrant's economics against this competitive landscape. For Titan Eyeplus specifically, public-domain disclosures provide a baseline view of operations, but segment-wise revenue, EBITDA, capacity utilisation, and forward capex plans are not separately broken out in many cases. Where the company is part of a listed group, the SEBI LODR and the Companies Act 2013 governance framework apply, with statutory audit conducted under SA 700 and CARO 2020 reporting. Where the company is unlisted, the Companies Act 2013 framework continues to govern with reduced public disclosure. The risk and opportunity outlook for Titan Eyeplus mirrors the broader eye care / optical store business plan & category dynamics. Demand-side drivers include rising household consumption, urbanisation, organised retail expansion, and policy support including PLI schemes (where applicable to the segment). Supply-side risks include input cost volatility, regulatory tightening, environmental compliance escalation, and competitive intensity from larger groups or imports. Management quality, balance sheet strength, distribution depth, and the capex execution track record are the differentiators within the peer set. KAMRIT's research desk maintains a baseline reference for Titan Eyeplus as a peer benchmark within the eye care / optical store business plan & category. For investors, lenders, or new entrant promoters seeking a fuller assessment of Titan Eyeplus, KAMRIT's deep-dive company profile engagement covers financial trajectory, capacity and capex, distribution and customer concentration, regulatory exposure, and the competitive position with named peers.

KAMRIT point of view

Building or competing with Titan?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the retail — eyewear & optical sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Titan and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 1 related project report → Book a scoping call

Related KAMRIT project reports

These reports use Titan Eyeplus in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.